Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Sep 20:9:10-14.
doi: 10.1016/j.jbo.2017.09.002. eCollection 2017 Nov.

Soft tissue recurrence of giant cell tumor of the bone: Prevalence and radiographic features

Affiliations

Soft tissue recurrence of giant cell tumor of the bone: Prevalence and radiographic features

Leilei Xu et al. J Bone Oncol. .

Abstract

Aim: Recurrence of giant cell tumor of bone (GCTB) in the soft tissue is rarely seen in the clinical practice. This study aims to determine the prevalence of soft tissue recurrence of GCTB, and to characterize its radiographic features.

Methods: A total of 291 patients treated by intralesional curettage for histologically diagnosed GCTB were reviewed. 6 patients were identified to have the recurrence of GCTB in the soft tissue, all of whom had undergone marginal resection of the lesion. Based on the x-ray, CT and MRI imaging, the radiographic features of soft tissue recurrence were classified into 3 types. Type I was defined as soft tissue recurrence with peripheral ossification, type II was defined as soft tissue recurrence with central ossification, and type III was defined as pure soft tissue recurrence without ossification. Demographic data including period of recurrence and follow-up duration after the second surgery were recorded for these 6 patients. Musculoskeletal Tumor Society (MSTS) scoring system was used to evaluate functional outcomes.

Results: The overall recurrence rate was 2.1% (6/291). The mean interval between initial surgery and recurrence was 11.3 ± 4.1 months (range, 5-17). The recurrence lesions were located in the thigh of 2 patients, in the forearm of 2 patients and in the leg of the other 2 patients. According to the classification system mentioned above, 2 patients were classified with type I, 1 as type II and 3 as type III. After the marginal excision surgery, all patients were consistently followed up for a mean period of 13.4 ± 5.3 months (range, 6-19), with no recurrence observed at the final visit. All the patients were satisfied with the surgical outcome. According to the MSTS scale, the mean postoperative functional score was 28.0 ± 1.2 (range, 26-29).

Conclusions: The classification of soft tissue recurrence of GCTB may be helpful for the surgeon to select the appropriate imaging procedure to detect the recurrence. In addition, the marginal resection can produce a favorable outcome for the patients.

Keywords: Giant cell tumor of bone; Prevalence; Radiographic features; Recurrence.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
A 44-year-old female patient with giant cell tumor in the proximal left fibula. (a–c) CT scan of the left leg at the 17th month after surgery showed soft tissue nodular lesions with eggshell-like peripheral hyperdense rim. (d) On the cross-sectional fat-suppressed T2-weighted MR image, soft tissue masses revealed inhomogeneous high signal intensity.
Fig. 2
Fig. 2
A 37-year-old male patient with giant cell tumor in the right ischium. (a–b) A centrally located ossification could be observed on both plain radiography and CT scan at the 9th month after surgery.
Fig. 3
Fig. 3
A 34-year-old female patient with giant cell tumor in the distal right femur. (a) There was no evidence of ossification in the soft tissue on plain radiography (b) The coronal T2-weighted MR image showed inhomogenous intermediate to high signal intensity.

References

    1. Rockberg J., Bach B.A., Amelio J., Hernandez R.K., Sobocki P., Engellau J., Bauer H.C., Liede A. Incidence trends in the diagnosis of giant cell tumor of bone in Sweden since 1958. J. Bone Jt. Surg. Am. Vol. 2015;97:1756–1766. - PubMed
    1. Arbeitsgemeinschaft K., Becker W.T., Dohle J., Bernd L., Braun A., Cserhati M., Enderle A., Hovy L., Matejovsky Z., Szendroi M., Trieb K., Tunn P.U. Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy. J. Bone Jt. Surg. Am. Vol. 2008;90:1060–1067. - PubMed
    1. Chanchairujira K., Jiranantanakorn T., Phimolsarnti R., Asavamongkolkul A., Waikakul S. Factors of local recurrence of giant cell tumor of long bone after treatment: plain radiographs, pathology and surgical procedures. J. Med. Assoc. Thail. = Chotmaihet Thangphaet. 2011;94:1230–1237. - PubMed
    1. Gouin F., Dumaine V., French S. Bone tumor study groups G-G. Local recurrence after curettage treatment of giant cell tumors in peripheral bones: retrospective study by the GSF-GETO (French Sarcoma and bone tumor study groups) Orthop. Traumatol. Surg. Res.: OSTR. 2013;99:S313–S318. - PubMed
    1. Balke M., Ahrens H., Streitbuerger A., Koehler G., Winkelmann W., Gosheger G., Hardes J. Treatment options for recurrent giant cell tumors of bone. J. Cancer Res. Clin. Oncol. 2009;135:149–158. - PMC - PubMed

LinkOut - more resources